| Name | Levomepromazine |
| Description | Levomepromazine (Methotrimeprazine) is an orally active aliphatic phenothiazine antipsychotic compound and a Ca2+ release inducer, exhibiting antiviral, anti-inflammatory, neuroprotective, analgesic, and anti-nociceptive activities. Levomepromazine inhibits dopaminergic, cholinergic, serotoninergic, and histaminergic receptors, and is used for research in neurodegenerative diseases. |
| In vitro | Levomepromazine(0.01-200 μM,72h) increased the CYP3A4 activity of HU1832 to 152% at 2.5 μM. [1]
Levomepromazine (10 μM, 24 h) reduced Japanese encephalitis virus (JEV) -induced Neuro2a cell death, decreased JEV RNA levels and viral titers, and significantly inhibited JEV protein translation/replication complex formation and ROS production.
Levomepromazine (10 μM, 24 h) reduces inflammation in microglia by inducing autophagy. [2] |
| In vivo | Levomepromazine (5-20 mg/kg; Intraperitoneal injection) has analgesic, sedative and anti-injurious effects in mice [4]. |
| Storage | Shipping with blue ice/Shipping at ambient temperature. |
| Solubility Information | 10% DMSO+40% PEG300+5% Tween 80+45% Saline : 1 mg/mL (3.04 mM), Sonication is recommended.
DMSO : 30 mg/mL (91.33 mM), Sonication is recommended.
|
| Keywords | Levomepromazine |
| Inhibitors Related | Calcium Propionate | Stavudine | Aceglutamide | Hemin | 2,4,6-Tri-tert-butylphenol | Guanidine hydrochloride | Benzyl propionate | Terbinafine hydrochloride | Hydroxychloroquine | Paeonol | Thymidine | Alginic acid |
| Related Compound Libraries | Bioactive Compound Library | Antidepressant Compound Library | Membrane Protein-targeted Compound Library | Anti-Fungal Compound Library | Neurotransmitter Receptor Compound Library | Anti-Viral Compound Library | Drug Repurposing Compound Library | Immunology/Inflammation Compound Library | Bioactive Compounds Library Max | Ion Channel Targeted Library | GPCR Compound Library | Anti-Infection Compound Library |
United States
